New targeted drug combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced colorectal cancer that has not been treated yet (no prior chemo or targeted therapy for this cancer).
- You are healthy enough to do normal daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan, and you have not had radiation to that tumor.
- You do not have untreated brain metastases, active bleeding, or severe heart/lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests whether adding a drug called bevacizumab (which helps stop blood vessel growth to tumors) to a combination of two chemotherapy drugs (oxaliplatin and TAS-102) can help people with advanced colorectal cancer. It is for people who have not yet received treatment for their advanced cancer.
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new targeted therapy (SHR-1811) for colorectal cancer that has grown despite initial chemotherapy. It may help people whose tumors have certain HER2 protein levels, offering a treatment option after standard therapy has stopped working.
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.